Literature DB >> 15610225

A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria.

Daniella Magen1, Eli Sprecher, Israel Zelikovic, Karl Skorecki.   

Abstract

BACKGROUND: Familial renal glucosuria (FRG) is an isolated disorder of proximal tubular glucose transport, characterized by abnormal urinary glucose excretion in the presence of normal blood glucose levels. Generalized aminoaciduria has not generally been considered a feature of this disorder. FRG has recently been shown to result from mutations in SLC5A2, encoding the kidney-specific low-affinity/high-capacity Na+/glucose cotransporter, SGLT2. The purpose of this study was to examine the phenotypic and genetic characteristics of three unrelated consanguineous families with FRG accompanied by aminoaciduria.
METHODS: Six children with autosomal-recessive FRG and 12 unaffected family members were evaluated at the clinical and molecular levels. DNA sequence analysis of the entire coding sequence of SLC5A2 was performed in all affected individuals. Haplotype analysis using four polymorphic markers flanking SLC5A2 was performed in all study participants.
RESULTS: All affected children were asymptomatic, but displayed massive glucosuria (83 to 169 g/1.73 m(2)/day) accompanied by generalized aminoaciduria. Sequence analysis in all patients revealed a novel homozygous missense mutation in exon 8 of SLC5A2, resulting in a lysine to arginine substitution at position 321 of SGLT2 amino acid sequence (K321R). The mutation was confirmed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and was found to completely cosegregate with the FRG phenotype. Haplotype analysis is consistent with identity by descent for the mutation. The K321 residue, presumed to be located in the eighth transmembrane domain of SGLT2, is highly conserved across SGLT homologues.
CONCLUSION: Our findings confirm that mutations in SLC5A2 result in autosomal-recessive FRG. The severe glucosuria in homozygotes for the K321R mutation highlights the importance of the eighth SGLT2 transmembrane domain for normal glucose transport. We suggest that the generalized aminoaciduria accompanying FRG is a consequence of the severe impairment in glucose reabsorption, and is probably not directly related to the SGLT2 mutation. The exact role of the aberrant glucose transport in the pathogenesis of aminoaciduria remains to be established.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15610225     DOI: 10.1111/j.1523-1755.2005.00053.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  29 in total

Review 1.  Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Authors:  Volker Vallon; Kumar Sharma
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Familial renal glucosuria: a clinicogenetic study of 23 additional cases.

Authors:  HyunKyung Lee; Kyoung Hee Han; Hye Won Park; Jae Il Shin; Chan Jong Kim; Mee Kyung Namgung; Kee Hyuck Kim; Ja Wook Koo; Woo Young Chung; Dae-Yeol Lee; Su-Yung Kim; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2012-07       Impact factor: 3.714

3.  Deleterious nonsynonymous single nucleotide polymorphisms in human solute carriers: the first comparison of three prediction methods.

Authors:  Da-Cheng Hao; Bing Xiao; Ying Xiang; Xue-Wei Dong; Pei-Gen Xiao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-04       Impact factor: 2.441

4.  The Sweet Pee model for Sglt2 mutation.

Authors:  Joseph P Ly; Tuncer Onay; Karen Sison; Gavasker Sivaskandarajah; Venkata Sabbisetti; Lingli Li; Joseph V Bonventre; Ann Flenniken; Neal Paragas; Jon M Barasch; S Lee Adamson; Lucy Osborne; Janet Rossant; Jurgen Schnermann; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2011-01       Impact factor: 10.121

5.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Authors:  Caroline Bonner; Julie Kerr-Conte; Valéry Gmyr; Gurvan Queniat; Ericka Moerman; Julien Thévenet; Cédric Beaucamps; Nathalie Delalleau; Iuliana Popescu; Willy J Malaisse; Abdullah Sener; Benoit Deprez; Amar Abderrahmani; Bart Staels; François Pattou
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

6.  Foamy Urine: Is This a Sign of Kidney Disease?

Authors:  Zeid J Khitan; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-01       Impact factor: 8.237

Review 7.  Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease.

Authors:  Miryam Cannizzaro; Jana Jarošová; Boel De Paepe
Journal:  J Appl Genet       Date:  2019-07-08       Impact factor: 3.240

8.  Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Authors:  Atsuo Tahara; Eiji Kurosaki; Masanori Yokono; Daisuke Yamajuku; Rumi Kihara; Yuka Hayashizaki; Toshiyuki Takasu; Masakazu Imamura; Li Qun; Hiroshi Tomiyama; Yoshinori Kobayashi; Atsushi Noda; Masao Sasamata; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-03       Impact factor: 3.000

9.  SGLT2 mediates glucose reabsorption in the early proximal tubule.

Authors:  Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

Review 10.  Developmental changes in renal tubular transport-an overview.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.